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Abstract
Background: Intermittent preventive treatment in children (IPTc) is a promising strategy to control malaria
morbidity. A significant concern is whether IPTc increases children’s susceptibility to subsequent malaria infection
by altering their anti-Plasmodium acquired immunity.
Methods: To investigate this concern, IgG antibody (Ab) responses to Plasmodium falciparum schizont extract were
measured in Senegalese children (6 months-5 years old) who had received three rounds of IPTc with artesunate +
sulphadoxine-pyrimethamine (or placebo) at monthly intervals eight months earlier. Potential confounding factors,
such as asexual malaria parasitaemia and nutritional status were also evaluated.
Results: Firstly, a bivariate analysis showed that children who had received IPTc had lower anti-Plasmodium IgG Ab
levels than the non-treated controls. When epidemiological parameters were incorporated into a multivariate
regression, gender, nutritional status and haemoglobin concentration did not have any significant influence. In
contrast, parasitaemia, past malaria morbidity and increasing age were strongly associated with a higher specific
IgG response.
Conclusions: The intensity of the contacts with P. falciparum seems to represent the main factor influencing anti-
schizont IgG responses. Previous IPTc does not seem to interfere with this parasite-dependent acquired humoral
response eight months after the last drug administration.
Background
Malaria elimination is now considered a realistic goal for
an increasing number of countries [1]. It requires con-
trol of the infection in the most at-risk groups, namely
pregnant women [2] and children [3]. The distribution
of anti-malarial drugs at predetermined regular intervals
(Intermittent Preventive Treatment, IPT) to individuals
regardless of their malaria status, already implemented
during pregnancy, is under clinical evaluation in infants
(IPTi, reviewed in [4]), and in preschool (IPTc, [5-9])
and school-aged children (IPTsc, [7,10,11]). Seasonal
IPTc (sIPTc) is defined as the administration of IPT to
children during the transmission season in locations
where malaria transmission is not perennial, mainly in
the African Sahelian belt. IPT strategies raise several
concerns which are under scrutiny, such as optimal
schedule, acceptability, drug resistance, implementation,
cost-efficiency, but one question requires an urgent
answer-does IPT impair the development of specific
immunity? IPT is able to clear a large number of circu-
lating parasites, thus reducing the amount of contacts
which are normally required to develop naturally
acquired immunity to malaria [12].
Additionally, immuno-suppression has been reported
from experimental studies of artemisinin-derivatives
[13]. In the case of IPTi, some individual trials provided
evidence that treated infants were subsequently, more
susceptible to malaria or anaemia, the so-called
“rebound effect” [14,15], but an overall analysis did not
show any evidence of rebound [16]. Attention was given
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and the infants’ response to EPI vaccines, which are
delivered at the same time [17-19]. However, only two
studies considered specific anti-Plasmodium immune
responses. In Mozambique, sulphadoxine-pyrimetha-
mine (SP) given at the age of three, four, and nine
months did not significantly modify the development of
naturally acquired antibody (Ab) responses to several
Plasmodium falciparum antigens up to 24 months of
age [20]. On the other hand, in Ghana, anti-schizont Ab
levels were significantly lower in children treated once
with SP than in controls [21]. In the latter study, IgG
levels were related to the frequency of past infections.
Two IPTc trials conducted in children less than five
years of age, have demonstrated a lack of a clinical
rebound-effect one year after IPT delivery, using SP +
artesunate in Senegal [6] and SP in Mali [7]. In Ghana
[9], malaria incidence during the post-intervention per-
iod was increased by 62% in infants who received six
monthly artesunate + amodiaquine, but this rebound
was not seen in children aged one year or more at the
time of drug administration. Immunological status,
known to be closely age-dependent, was not assessed in
any of these IPTc trials. Therefore, the objective of the
present study was to check whether IPTc had any
impact on the anti-Plasmodium IgG response in the
Senegalese study [6], eight months after the last IPT
delivery. To improve our understanding of the mode of
action of IPT [4,22], epidemiological features of the
study children were incorporated as potential confound-
ing factors in a multivariate analysis.
Methods
Cohort follow-up
The study population came from the community of
Niakhar, situated in Central Senegal, 145 km east from
Dakar, where regular demographic surveillance has
been maintained since 1963 [23]. It is an open savan-
nah area, with less than 500 mm of rainfall per year.
Malaria transmission is markedly seasonal and classi-
fied as mesoendemic, with most infections occurring
between July and October and most clinical cases
occuring in September-October. The average entomo-
logical inoculation rate is 10 infective bites per year
with sharp variations between villages depending on
their distance to the closest Anopheles larval breeding
sites [24]. In 2002, a double-blind, randomized, pla-
cebo-controlled trial demonstrated, on an initial cohort
of 1203 children (6 weeks to 5 years old), that a combi-
nation of artesunate and SP administered preventively
on a monthly basis between September and November
reduced the number of malaria attacks in treated chil-
dren by 86% [6]. The active (weekly domiciliary visits)
and passive (dispensaries) detections of malaria cases
relied on clinical symptoms as previously defined [6]
a n du s e dap a r a s i t ed e n s i t yo f3 , 0 0 0P. falciparum
asexual stage parasites/μl as the minimal threshold to
consider a case as one of confirmed malaria. A cross-
sectional survey was done in December 2002, in order
to measure the impact of IPTc on the prevalence of
children with parasitaemia, parasites resistant to sul-
phadoxine-pyrimethamine and anaemia at the end of
the clinical follow-up period, and seven months later,
in July 2003, before the beginning of the next rainy
season. Anthropometric measurements were collected
as previously described [25]. Capillary blood smears
were made from a fingerprick sample, allowing the
assessment of Plasmodium asexual blood stages parasi-
taemia. Haemoglobin concentrations were measured in
a HemoCue Machine® as previously described [6]. Sera
were obtained by centrifugation then stored at -20°C
until tested. From the 929 children who attended the
cross-sectional survey in July2 0 0 3 ,ar a n d o m i z a t i o nl i s t
was computer generated and a subsample of 350 chil-
dren was selected for serological screening. 12 blood
samples could not be technically processed, leaving 338
available for assay.
Ethics
Approval of the study was obtained from the ethical
review committees of the Senegalese government, the
French Institute of Research for Development, and the
London School of Hygiene and Tropical Medicine.
Informed consent was obtained from parents or guar-
dians before any child was included in the study.
Evaluation of anti-Plasmodium IgG levels by ELISA
IgG antibodies were screened using a biotin-avidin
amplified indirect ELISA. Plasmodium falciparum schi-
zont extract was obtained from infected erythrocytes
and coated on flat-bottom microtiter plates (Nunc,
Roskilde, Denmark) at a concentration of 2 μg/ml.
After blocking the plates with gelatin 0.5% in PBS, the
plasma samples and a mouse biotinylated mAb to
human IgG (BD Pharmingen, San Diego CA, USA)
were successively diluted in PBS-Tween 0.1% at 1:100
and 1:1000, respectively. After incubation with a perox-
idase-conjugated streptavidin (Amersham Biosciences,
les Ulis, France), ABTS (2.2’-azino-bis (3-ethylbenzthia-
zoline 6-sulfonic acid) diammonium, Sigma, St Louis,
MO, USA) was added and optical density (OD) was
measured at 405 nm. All sera were tested in duplicate
wells coated with antigen together with a third single
uncoated well to take into account non-specific bind-
ings. A pool of positive sera was run in all the plates
allowing adjustments for inter-plate variations. A nega-
tive pool (non-exposed European individuals) was also
included in each plate.
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Comparisons between medians used the Mann-
Whitney test. Multivariate hierarchical linear regression
was performed to identify variables independently asso-
ciated with antibody measurements. Since these were
not normally distributed, optical densities were log
transformed. Potential covariates entered in the model
were: the treatment group (IPT vs placebo), age (12-24;
24-36; 36-48; 48-60 and ≥ 60 months old at the time of
blood sampling), sex, nutritional status (normal;
wasted; stunted as previously described [26]) assessed
in November 2002 and in July 2003, number of malaria
attacks between September and December 2002
(continuous), presence of blood asexual stages of
P. falciparum in December 2002 and in July 2003,
haemoglobin concentration (g/dL) in July 2003 (contin-
uous). Reference categories were as follows: females
(gender), two years old class (age), normal (nutritional
status), no malaria case (morbidity), no detected tro-
phozoite (parasitaemia) and lowest value (haemoglo-
bin). To account for the hierarchical structure of the
data (groups of children sampled in 11 different vil-
lages), we included a random effect component at the
village level in the regression model. Significance of the
random effect was tested using a likelihood ratio test.
Analyses were performed using the Stata software
(Version 10.0; Stata Corp., College Station, TX). The
significance limit was P < 0.05.
Results
Cohort description
The 338 sampled children (49.1% males) lived in 11 vil-
lages (8-66 per village) and 158 (46.7%) received IPT in
2002. In this sub-sample, the overall malaria incidence
in 2002 was 0.406 (placebo) and 0.089 (IPT) cases/child
over the 3.5 months follow-up. Villages differed signifi-
cantly in terms of parasite rates, ranging from 0 to
43.2% in December 2002 and from 4.8 to 42.9% in July
2003 (P = 0.007 and 0.006, respectively).
Influence of 2002 treatment on anti-Plasmodium IgG
responses
Bivariate analysis
Levels of IgG Ab against P. falciparum schizont in sera
collected in July 2003 from children who had received
either IPT or a placebo the previous year are shown in
F i g u r e1 .T h em e d i a na n t i b o d yl e v e li nt h eI P T cg r o u p
was significantly lower by one-third compared to the
non-treated controls (Mann-Whitney, P < 0.05). Consid-
ering the heterogeneity of the O.D. distributions within
each group, potential confounding factors were incorpo-
rated into a multivariate model.
Multivariate analysis of potential confounding
epidemiological factors
Data were available from the 338 children except for
information on parasitaemia for 48 children in Decem-
ber 2002 and 33 in July 2003 (Table 1). When covariates
were introduced into the multivariate model, the 2002
treatment group, gender, nutritional status and haemo-
globin concentration did not appear to have a significant
influence on the IgG titres although stunting in July
2003 tended to be associated with a lower response
without reaching statistical significance (P = 0.144). In
contrast, age was positively and strongly associated with
increasing anti-Plasmodium Ab levels (Figure 2), espe-
cially in the older children. Similarly, carriage of Plasmo-
dium asexual stages, both at the end of the first
transmission season (December 2002) and at the begin-
ning of the following transmission season (July 2003),
was associated with a high Ab response, irrespective of
the treatment received in 2002. Median IgG Ab levels
were 5.2 (CI95%: 3.7-7.1) and 6.8 (CI95%: 5.4-8.0) times
higher in parasitaemic children compared to blood film
negative children at both cross-sectional surveys
(Figure 3). In addition, the number of malaria attacks
experienced in 2002 was positively linked to anti-
Plasmodium IgG levels (data not shown). Village of resi-
dence had a significant (P = 0.007) impact on antibody
levels. The highest median specific IgG levels were
observed in the villages closest to potential mosquito
larval breeding sites (data not shown). No interaction
was found between the covariates.
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Figure 1 IgG antibodies against Plasmodium falciparum
schizont extract measured in July 2003. Children received, in
September-October-November 2002, either intermittent preventive
treatment (IPTc) with artesunate + sulphadoxine-pyrimethamine or
placebo (controls). Bars indicate the median value for each group.
The two groups were compared using a bivariate Mann-Whitney
test.
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Despite some debate on its efficacy, evidence is growing
that IPT is a potentially valuable tool to control malaria
in young children [27]. It may be particularly useful in
areas with seasonal malaria transmission where drug
delivery can be focused on a limited period of time
when transmission and malaria risk are maximal. How-
ever, the potential negative effect of IPT on the develop-
ment of natural acquired immunity against the parasite
remains an important point to be investigated [28]. The-
oretically, IPT could interfere with the anti-Plasmodium
immune response via two main distinct mechanisms,
either by a direct immunosuppressor effect of the drugs
or, indirectly, by reducing contacts between the treated
child and Plasmodium thus impairing immunity devel-
opment. There is already evidence to support the latter
mechanism in the case of weekly chemoprophylaxis [29]
and this has led to concerns over its widespread use.
Unlike some other classes of anti-malarial molecules,
including the 4-aminoquinolones [30,31], neither SP or
artesunate is thought to be immunosuppressive. More-
over, several IPTi trials (reviewed by [32]) have shown
that SP and artesunate did not have an effect, positive
or negative, on the infant response to various childhood
vaccines (diphtheria, tetanus, pertussis, polio, hepatitis
B, Hib, measles). The most likely mechanism by which
IPTc reduces malaria morbidity combines therapeutic
(clearing of existing infections) and preventive (allowing
immunity development) effects, the prophylactic effect
being predominant [33]. IPTi studies have shown that in
areas where P. falciparum is still susceptible to SP, a
single dose of SP provides infants with a protection last-
ing from 4-6 weeks [34] to 30-60 days [35] according to
the setting, as might be anticipated from the half lives of
the component drugs.
The present study showed that children less than five
years who had received preventively the combination of
SP + artesunate during the rainy season had a slightly
lower level of anti-Plasmodium schizont Abs compared
to non-treated control children at the beginning of the
next transmission season, eight months later. These
findings are in agreement with the reduced anti-schizont
IgG response measured in Ghanaian infants six months
after a single dose of SP given alone [21] although this
study differed in several aspects, noticeably in the age of
the participants (malaria-naïve infants in Ghana versus
1-6 years old children with some immunity in Senegal)
and on the endemicity levels (perennial transmission in
rural Ghana with 400 infective bites per person-year
[36] versus seasonal transmission in Senegal with 10
infective bites per year [24]).
In a multivariate model, four co-variables significantly
influenced anti-Plasmodium IgG levels: age, village, past
malaria morbidity and Plasmodium carriage. Age was a
major determinant of specific IgG titres, especially
among children older than four years. This is in agree-
ment with findings in Northern Senegal where anti-schi-
zont IgG responses increased progressively in one to
Table 1 Multivariate mixed-effect regression model of anti-schizont IgG by treatment group
Variables Period Estimates P-value 95% Confidence interval
Treatment group 2002 0.112 0.379 -0.137 0.360
Gender - -0.031 0.787 -0.255 0.193
Age class
3 years (y) 2003 0.410 0.036 0.027 0.793
4 y 2003 0.733 <0.0001 0.375 1.091
5 y 2003 0.919 <0.0001 0.530 1.308
6 y 2003 1.035 <0.0001 0.631 1.439
Stunting November 2002 0.043 0.814 -0.315 0.401
July 2003 -0.253 0.144 -0.592 0.086
Wasting November 2002 0.017 0.933 -0.393 0.428
July 2003 -0.011 0.963 -0.492 0.469
Malaria morbidity 2002 0.243 0.034 0.018 0.468
Parasitaemia December 2002 0.573 <0.0001 0.308 0.839
July 2003 0.931 <0.0001 0.653 1.210
Haemoglobin July 2003 0.003 0.936 -0.082 0.089
Constant term - -1.330 0.005 -2.257 -0.404
Random-effects parameters
Village - 0.244 - 0.114 0.520
Residual - 0.884 - 0.807 0.969
Gender, age, nutritionnal status and malaria indicators were evaluated as potentially confounding factors, village as a random factor. P values were considered as
significant when <0.05.
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nine years of age [37]. Age-associated maturation of the
immune system, cumulative impact of mosquito infect-
ing bites and production by the oldest children of long-
lived plasma cells [38] may explain the natural influence
of age. In accordance with what was observed in
Mozambique [20] and in Ghana [21], children who
experienced clinical attacks of malaria had higher anti-
Plasmodium IgG responses in July 2003 than those who
did not become sick. These observations suggest that
release into the bloodstream of large numbers of schi-
zont-derived Plasmodium stages during a malaria attack
provides substantial antigenic stimulation to the
immune effector cells. As reported in the two IPTi anti-
body surveys previously quoted [20,21], Plasmodium
carriage at the time of blood sampling (July 2003) was
associated with a strikingly higher anti-schizont IgG
response. Increased humoral responses to various
antigens in parasitized children compared to controls is
a consistent observation [37,39], reflecting an increased
exposure of the immune system to blood-stage parasites.
Similarly, differences in the frequency of infectious ano-
phelines bites [24] may account for the observed signifi-
cant heterogeneity of specific IgG titres between villages.
Surprisingly, parasite carriage seven months before the
blood sampling was also strongly and positively linked
to a high specific Ab response. Interestingly, parasite
rates did not change significantly during the 2003 dry
season suggesting that parasites can persist in humans
from one transmission season to the other and elicit a
steady production of specific Abs through continuous
antigenic stimulation. Taken as a whole, it appears that
the level of anti-Plasmodium schizont Abs at a given
time reflects a cumulative process of specific immuno-
globulin production positively related to the level of
contact between the host immune system and blood-
IPT control IPT control IPT control IPT control IPT control
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Figure 2 Anti-Plasmodium falciparum schizont IgG levels in July 2003.A n t i - Plasmodium falciparum schizont IgG antibodies in 338 children
presented according to their age class and to the treatment they received in September-October-November 2002 (IPT or placebo). Bars indicate
the median value for each sub-group. P values drawn for comparisons between the age groups obtained using multivariate analysis (see Table
1) are displayed above the frame. P values obtained by comparing the IPT and control groups using bivariate analysis (Mann-Whitney test) are
displayed within the frame. yo: years old
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Figure 3 Anti-Plasmodium falciparum schizont IgG levels in July 2003. A comparison of anti-Plasmodium falciparum schizont IgG antibodies
in 290 children surveyed in December 2002 (panel A) and in 305 children surveyed in July 2003 (panel B) by parasite status. All children had
received IPT or placebo in September, October and November. The P value between the IPT and the control groups originates from a
multivariate analysis (see Table 1) whereas Mann-Whitney tests were used to compare Plasmodium carriers to non-carriers. Bars indicate the
median value for each sub-group.
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carriage is the key factor for anti-schizont IgG produc-
tion, irrespective of the preventive treatment received,
although the possibility of some contributory effect from
the antimalarial drugs used for IPT cannot be comple-
tely excluded.
Conclusions
To conclude, administration of SP and artesunate used
as sIPTc slightly decreased the humoral reactivity to a
crude Plasmodium extract. Specific IgG Abs appeared to
increase with the amount of exposure to Plasmodium
asexual stages at the time of blood sampling but also to
exposure during the previous 10 months. A more accu-
rate analysis of the immune response, looking at differ-
ent putatively protective isotypes and antigens [40],
would be valuable. Previous studies have shown, in The
Gambia, that stopping chemoprophylaxis after a period
of several years increased the risk of clinical malaria
[41]. Monitoring the potential rebound effect in children
who will receive IPTc for several consecutive years will
also be of great interest [42].
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